web analytics

Isofol’s drug candidate arfolitixorin receives clinical patent approval in the United States

GOTHENBURG, Sweden, May 21, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL), today announced approval of a clinical patent for arfolitixorin in the United States. The patent expires in 2038 and is the first in a series of clinical patent applications to reach grant.  It relates to a method of increasing blood concentration of deoxyuridine, a blood biomarker for inhibition of tumor growth in human cancer treatment.
Specifically, the now granted patent US 10,292,984 is directed towards a dose regime for the combination of arfolitixorin and 5-fluorouracil injections to

Source: Isofol’s drug candidate arfolitixorin receives clinical patent approval in the United States

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.